- Home
- DRDB vs OSUR Comparison
DRDB vs OSUR Comparison
Compare DRDB & OSUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DRDB | OSUR |
|---|---|---|
| Founded | 2024 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.5M | 177.2M |
| IPO Year | 2024 | 1986 |
Fundamental Metrics
Financial Performance| Metric | DRDB | OSUR |
|---|---|---|
| Price | $10.43 | $2.51 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 55.9K | ★ 851.7K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,703,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.70 |
| P/E Ratio | $597.54 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.87 | $2.08 |
| 52 Week High | $10.47 | $4.22 |
Technical Indicators
Market Signals| Indicator | DRDB | OSUR |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 49.89 |
| Support Level | $10.44 | $2.42 |
| Resistance Level | $10.45 | $2.65 |
| Average True Range (ATR) | 0.01 | 0.12 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 27.27 | 61.64 |
Price Performance
Historical ComparisonAbout DRDB Roman DBDR Acquisition Corp. II Ordinary shares
Roman DBDR Acquisition Corp II is a blank check company.
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.